15 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has grown 3.6% per year over the past 5 years.
Net income has grown faster than revenue (133.3% vs 3.6% per year).
Operating margin has expanded, at 34.0% in the latest year.
Free cash flow has grown 4.7% per year over the past 5 years.
Financial health
Total debt ($24.9B) exceeds cash ($7.6B); net debt is $17.4B.
Total debt has grown slower than revenue (-4.5% vs 3.6% per year).
Operating income covered interest expense 9.8× in the latest year.
Total debt is 2.5× EBITDA.
Shareholder returns
Dividends have been paid for 11 consecutive years, consuming 47.0% of earnings and 42.3% of free cash flow.
The dividend has grown 3.0% per year over the past 5 years.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
2025
$29.4B
$8.5B
78.8%
34.0%
$9.5B
$24.9B
$7.6B
2024
$28.8B
$480M
78.3%
5.8%
$10.3B
$26.7B
$10.0B
2023
$27.1B
$5.7B
76.0%
28.0%
$7.4B
$25.0B
$6.1B
2022
$27.3B
$4.6B
79.3%
26.9%
$8.3B
$25.2B
$5.4B
2021
$27.3B
$6.2B
75.8%
36.3%
$10.8B
$26.7B
$5.3B
2020
$24.7B
$123M
81.5%
16.5%
$7.5B
$31.4B
$6.0B
2019
$22.4B
$5.4B
79.2%
19.1%
$8.3B
$24.6B
$11.6B
2018
$22.1B
$5.5B
78.1%
37.1%
$7.5B
$27.3B
$17.9B
2017
$26.1B
$4.6B
83.3%
54.1%
—
$33.5B
$7.6B
2016
$30.4B
$13.5B
86.0%
58.0%
—
$26.3B
$8.2B
2015
—
$18.1B
—
—
—
$22.1B
—
2014
—
$12.1B
—
—
—
$12.4B
—
2013
—
$3.1B
—
—
$3.0B
$6.6B
—
2012
—
$2.6B
—
—
—
$8.2B
—
2011
—
$2.8B
—
—
—
$7.6B
—
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
Mar '26
$7.0B
$2.0B
79.2%
37.2%
$2.4B
$22.2B
$7.6B
Dec '25
$7.9B
$2.2B
79.5%
25.0%
$3.1B
$24.9B
$7.6B
Sep '25
$7.8B
$3.1B
79.8%
42.8%
$4.0B
$24.9B
$7.3B
Jun '25
$7.1B
$2.0B
78.8%
34.9%
$720M
$24.9B
$5.1B
Mar '25
$6.7B
$1.3B
76.9%
33.6%
$1.7B
$25.0B
$7.9B
Dec '24
$7.6B
$1.8B
79.1%
32.4%
$2.8B
$26.7B
$10.0B
Sep '24
$7.5B
$1.3B
79.1%
11.8%
$4.2B
$23.2B
$5.0B
Jun '24
$7.0B
$1.6B
77.8%
38.0%
$1.2B
$23.3B
$2.8B
Mar '24
$6.7B
-$4.2B
76.8%
-64.6%
$2.1B
$25.2B
$4.7B
Dec '23
$7.1B
$1.4B
70.6%
22.7%
$2.0B
$25.0B
$6.1B
Sep '23
$7.1B
$2.2B
77.8%
37.2%
$1.6B
$25.0B
$5.7B
Jun '23
$6.6B
$1.0B
78.1%
25.2%
$2.2B
$25.2B
$5.7B
Mar '23
$6.4B
$1.0B
77.9%
26.8%
$1.6B
$25.2B
$4.9B
Dec '22
$7.4B
$1.6B
81.1%
30.7%
$2.4B
$25.2B
$5.4B
Sep '22
$7.0B
$1.8B
80.2%
40.3%
$2.7B
$25.2B
$4.7B
Jun '22
$6.3B
$1.1B
77.0%
32.4%
$1.7B
$26.2B
$4.7B
Mar '22
$6.6B
$19M
78.4%
3.0%
$1.6B
$26.2B
$4.3B
Dec '21
$7.2B
$382M
63.7%
13.0%
$3.0B
$26.7B
$5.3B
Sep '21
$7.4B
$2.6B
83.5%
51.8%
$3.1B
$27.7B
$4.4B
Jun '21
$6.2B
$1.5B
77.6%
36.1%
$2.2B
$30.2B
$4.9B
Valuation over time
How the market has priced GILD against its own fundamentals since 2023-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-earnings ratio has fallen from 22.4× (Mar '23) to 18.1× (Jun '26).
The price-to-sales ratio has risen from 3.8× (Mar '23) to 5.2× (Jun '26).
The dividend yield has fallen from 3.6% (Mar '23) to 2.6% (Jun '26).
Price / earnings (P/E)
P/E
Price / sales (P/S)
P/S
Dividend yield (%)
Dividend yield %
Frequently asked questions
Is GILD growing its revenue and profit?
Over the past 5 years, Gilead Sciences's revenue has grown 3.6% per year, and net income grown 133.3% per year. These are computed facts, not advice.
How much debt does GILD have?
As of FY2025, Gilead Sciences reported $24.9B of total debt against $7.6B of cash; operating income covered interest expense 9.8×.
What is GILD's profit margin?
In FY2025, gross margin was 78.8%, operating margin 34.0%, and net margin 28.9%.
What is GILD's P/E ratio?
As of Jun '26, Gilead Sciences traded at a price-to-earnings ratio of about 18.1× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.